Bad blood

John Carreyrou’s Bad Blood: Secrets and Lies in a Silicon Valley Startup is a gripping investigative account of the rise and fall of Theranos, the blood-testing company founded by Elizabeth Holmes in 2003. Holmes, a Stanford dropout who idolized Steve Jobs, convinced investors, board members, and the public that she had developed a revolutionary technology capable of running hundreds of diagnostic tests from a single finger-prick of blood. At its peak, Theranos was valued at nine billion dollars and Holmes was celebrated as the world’s youngest female self-made billionaire. Carreyrou, a Wall Street Journal reporter who broke the story, reconstructs how the entire enterprise was built on fraud — the technology never worked as advertised, and patients received dangerously inaccurate medical results.

The book reads with the pace of a thriller while remaining rigorously reported. Carreyrou draws on interviews with dozens of former employees, many of whom spoke at great personal and legal risk, to show how Holmes and her partner Sunny Balwani created a culture of secrecy, intimidation, and paranoia inside the company. Dissenters were fired or threatened with lawsuits. Whistleblowers were surveilled. The board, stacked with luminaries like George Shultz and James Mattis, was kept in the dark and largely failed to ask hard questions. What emerges is not just a story about one fraudulent company but a meditation on how Silicon Valley’s “fake it till you make it” ethos, combined with the cult of the charismatic founder, can become genuinely dangerous when applied to healthcare.

Carreyrou’s voice is precise and restrained, which makes the story all the more damning. He rarely editoralizes; he simply lays out the facts and lets the behavior speak for itself. The narrative centers on the human cost — patients who made medical decisions based on faulty lab results — while also capturing the systemic failures that allowed Holmes to operate for so long. Bad Blood is ultimately a cautionary tale about the seduction of a compelling story, and how desperately investors, regulators, and the media sometimes want a visionary to be real.

Key takeaways

The core technology never functioned. Theranos’s proprietary Edison machine could reliably run only a handful of tests; the company secretly used conventional third-party analyzers from Siemens and others for the vast majority of its tests, diluting samples in ways that introduced additional error.
Intimidation was a management strategy. Holmes and Balwani routinely fired employees who raised technical concerns and retained the law firm Boies Schiller to threaten former employees with litigation, creating a chilling effect that silenced critics for years.
The board’s prestige masked its ineffectiveness. Theranos’s directors were chosen for their political and military stature rather than scientific or medical expertise, and Holmes deliberately withheld technical information from them, demonstrating how governance can fail when a board is dazzled by a founder’s vision.
Regulatory blind spots enabled the fraud. Because Theranos marketed its tests as a “laboratory developed” service rather than a medical device, it avoided FDA oversight for years. The Centers for Medicare and Medicaid Services eventually stepped in, but only after patients had already been harmed.
George Shultz’s grandson Tyler was a pivotal whistleblower. As a young Theranos employee, Tyler Shultz attempted to report problems internally and then to regulators, defying his own grandfather, who remained a Holmes loyalist — a subplot that illustrates the personal costs of speaking truth to power.
Silicon Valley’s storytelling culture is a systemic risk. The book argues implicitly that the same narrative-driven fundraising environment that produces genuine innovation also creates fertile ground for fraud, because investors often bet on founders rather than products and are reluctant to probe too deeply.
The human stakes were concrete and serious. Patients received false positives for cancer and HIV, and false negatives for conditions requiring treatment; the fraud was not merely financial but medical, raising ethical questions about the entire direct-to-consumer lab testing model.